Upstream Bio Inc (UPB)

$5.48 -0.33 (-5.68%)
Market Cap 318.22M
Revenue (ttm) 2.85M
Net Income (ttm) -143.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,032.98%
Debt to Equity Ratio 0.00
Volume 421,200
Avg Vol 583,308
Day's Range N/A - N/A
Shares Out 54.77M
Stochastic %K 2%
Beta 1.28
Analysts Strong Sell
Price Target $33.67

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Xrx12
Xrx12 Sep. 16 at 12:14 AM
$UPB bid is at 4.99 overnight. Get ready for a colossal collapse
0 · Reply
Xrx12
Xrx12 Sep. 15 at 1:48 PM
$UPB possible to see 4s soon here
0 · Reply
Xrx12
Xrx12 Sep. 10 at 7:18 PM
$UPB still another 20% drop likely coming
0 · Reply
Xrx12
Xrx12 Sep. 10 at 3:03 PM
$UPB once this reaches a dollar ill buy a lot of shares
1 · Reply
Xrx12
Xrx12 Sep. 9 at 3:42 PM
$UPB down we go!
0 · Reply
Merlintrader
Merlintrader Sep. 8 at 4:31 PM
Biotech Radar | September 9 edition $ROIV $BEAM $UPB $BMY: clinical progress, evidence and next steps. News through September 8. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/biotech-radar-september-9-2026/
0 · Reply
Trainguy1
Trainguy1 Sep. 8 at 12:57 PM
$UPB Verekitug’s efficacy for reducing asthma exacerbations appears comparable to Tezspire’s, However, Verekitug can be administered less frequently. Both therapeutics demonstrated a low incidence of serious TEAEs.
0 · Reply
Megabyte48
Megabyte48 Sep. 8 at 11:01 AM
$UPB Phase2 data dropped
0 · Reply
STACKD0E
STACKD0E Sep. 8 at 10:16 AM
$OSTX $UPB $GMHS $SORA 👁
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 8 at 9:38 AM
$UPB Consistent with previous findings however Tezspire (tezepelumab) from AstraZeneca and Amgen significantly reduces the annualized asthma exacerbation rate by 56% to 71%. So Verekitug is second best
1 · Reply
Latest News on UPB
Upstream Bio presents results from VALIANT trial at ERS Congress

2026-09-08T09:10:19.000Z - 8 days ago

Upstream Bio presents results from VALIANT trial at ERS Congress

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Sep 8, 2026, 3:30 AM EDT - 8 days ago

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps

2026-09-01T13:15:32.000Z - 14 days ago

Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Sep 1, 2026, 7:00 AM EDT - 14 days ago

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Upstream Bio price target lowered to $25 from $43 at Truist

2026-08-17T09:22:30.000Z - 4 weeks ago

Upstream Bio price target lowered to $25 from $43 at Truist

Upstream Bio price target raised to $9 from $8 at JPMorgan

2026-08-16T13:38:40.000Z - 4 weeks ago

Upstream Bio price target raised to $9 from $8 at JPMorgan

Upstream Bio price target lowered to $25 from $43 at Truist

2026-08-11T18:55:22.000Z - 5 weeks ago

Upstream Bio price target lowered to $25 from $43 at Truist

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

2026-08-11T11:15:27.000Z - 5 weeks ago

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

Upstream Bio Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 5 weeks ago

Upstream Bio Earnings release: Q2 2026

Upstream Bio Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 5 weeks ago

Upstream Bio Quarterly report: Q2 2026

Upstream Bio Slides: Corporate presentation

Aug 11, 2026, 7:00 AM EDT - 5 weeks ago

Upstream Bio Slides: Corporate presentation

Upstream Bio management to meet with Piper Sandler

2026-06-17T20:20:10.000Z - 3 months ago

Upstream Bio management to meet with Piper Sandler

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

2026-06-14T20:55:54.000Z - 3 months ago

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Jun 14, 2026, 10:00 AM EDT - 3 months ago

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Jun 12, 2026, 5:07 PM EDT - 3 months ago

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

2026-06-12T08:55:22.000Z - 3 months ago

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 10:40 AM EDT - 3 months ago

Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Upstream Bio Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 3 months ago

Upstream Bio Transcript: AGM 2026

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Jun 8, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio initiated with a Buy at H.C. Wainwright

2026-06-03T10:11:07.000Z - 3 months ago

Upstream Bio initiated with a Buy at H.C. Wainwright

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

2026-05-18T15:35:26.000Z - 4 months ago

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

May 18, 2026, 11:30 AM EDT - 4 months ago

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio price target lowered to $50 from $51 at Mizuho

2026-05-14T12:37:47.000Z - 4 months ago

Upstream Bio price target lowered to $50 from $51 at Mizuho

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 7:00 AM EDT - 4 months ago

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Upstream Bio Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Upstream Bio Earnings release: Q1 2026

Upstream Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Upstream Bio Quarterly report: Q1 2026

Upstream Bio Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 4 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

2026-04-17T11:07:21.000Z - 5 months ago

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Apr 17, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Upstream Bio Proxy statement: Proxy filing

Upstream Bio Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Upstream Bio Proxy statement: Proxy filing

Upstream Bio Slides: Corporate presentation

Apr 6, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

2026-03-27T10:45:28.000Z - 5 months ago

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio Annual report: Q4 2025

Upstream Bio Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio Earnings release: Q4 2025

Upstream Bio Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 6 months ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 6 months ago

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Upstream Bio announces verekitug met the primary endpoint

2026-03-01T16:35:25.000Z - 6 months ago

Upstream Bio announces verekitug met the primary endpoint

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Mar 1, 2026, 9:45 AM EST - 6 months ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 26, 2026, 7:00 AM EST - 6 months ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 6 months ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio Transcript: Study result

Feb 11, 2026, 8:00 AM EST - 7 months ago

Upstream Bio Transcript: Study result

Upstream Bio Press release: Study result

Feb 11, 2026, 8:00 AM EST - 7 months ago

Upstream Bio Press release: Study result

Upstream Bio Slides: Study result

Feb 11, 2026, 8:00 AM EST - 7 months ago

Upstream Bio Slides: Study result

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 11, 2026, 6:00 AM EST - 7 months ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Feb 10, 2026, 6:00 PM EST - 7 months ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 8 months ago

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 8 months ago

Upstream Bio Slides: 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 8 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 8 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:25 AM EST - 9 months ago

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:30 PM EST - 9 months ago

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 9 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:30 AM EST - 10 months ago

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:20 AM EST - 10 months ago

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Upstream Bio Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 10 months ago

Upstream Bio Slides: Corporate Presentation

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 10 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Upstream Bio Quarterly report: Q3 2025

Upstream Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Upstream Bio Earnings release: Q3 2025

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 11 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 10:30 AM EDT - 1 year ago

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Transcript: Study Update

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Transcript: Study Update

Upstream Bio Press release: Study Update

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Press release: Study Update

Upstream Bio Slides: Study Update

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Slides: Study Update

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 1 year ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 1 year ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Upstream Bio Earnings release: Q2 2025

Upstream Bio Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Upstream Bio Quarterly report: Q2 2025

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 1 year ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Quarterly report: Q1 2025

Upstream Bio Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Earnings release: Q1 2025

Upstream Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Proxy statement: Proxy Filing

Upstream Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Proxy statement: Proxy Filing

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio Earnings release: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Earnings release: Q4 2024

Upstream Bio Annual report: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Annual report: Q4 2024

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:00 PM EST - 1 year ago

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Upstream Bio Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Upstream Bio Quarterly report: Q3 2024

Upstream Bio Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Upstream Bio Earnings release: Q3 2024

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Xrx12
Xrx12 Sep. 16 at 12:14 AM
$UPB bid is at 4.99 overnight. Get ready for a colossal collapse
0 · Reply
Xrx12
Xrx12 Sep. 15 at 1:48 PM
$UPB possible to see 4s soon here
0 · Reply
Xrx12
Xrx12 Sep. 10 at 7:18 PM
$UPB still another 20% drop likely coming
0 · Reply
Xrx12
Xrx12 Sep. 10 at 3:03 PM
$UPB once this reaches a dollar ill buy a lot of shares
1 · Reply
Xrx12
Xrx12 Sep. 9 at 3:42 PM
$UPB down we go!
0 · Reply
Merlintrader
Merlintrader Sep. 8 at 4:31 PM
Biotech Radar | September 9 edition $ROIV $BEAM $UPB $BMY: clinical progress, evidence and next steps. News through September 8. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/biotech-radar-september-9-2026/
0 · Reply
Trainguy1
Trainguy1 Sep. 8 at 12:57 PM
$UPB Verekitug’s efficacy for reducing asthma exacerbations appears comparable to Tezspire’s, However, Verekitug can be administered less frequently. Both therapeutics demonstrated a low incidence of serious TEAEs.
0 · Reply
Megabyte48
Megabyte48 Sep. 8 at 11:01 AM
$UPB Phase2 data dropped
0 · Reply
STACKD0E
STACKD0E Sep. 8 at 10:16 AM
$OSTX $UPB $GMHS $SORA 👁
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 8 at 9:38 AM
$UPB Consistent with previous findings however Tezspire (tezepelumab) from AstraZeneca and Amgen significantly reduces the annualized asthma exacerbation rate by 56% to 71%. So Verekitug is second best
1 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 8 at 9:14 AM
$UPB https://www.stocktitan.net/news/UPB/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-vo0cjr49wgjc.html
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 8 at 9:09 AM
$UPB Great data
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 8 at 9:08 AM
$UPB https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html
0 · Reply
Megabyte48
Megabyte48 Sep. 5 at 10:13 AM
$UPB I got a little let’s see how the phase updates go, i mean someone bought 102k shares at 6.01 so why not.
0 · Reply
Xrx12
Xrx12 Sep. 4 at 8:12 PM
$UPB wonder if we see $1.0 by next year
0 · Reply
SimplyFussFree
SimplyFussFree Sep. 4 at 7:11 AM
$UPB I’m simultaneously upset I have funds tied up here with it going nowhere lately, yet reluctant to sell because I’m still optimistic…
2 · Reply
Xrx12
Xrx12 Sep. 3 at 5:40 PM
$UPB no bounce from the 52 week low and no buying pressure. This thing is going all the way down
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Sep. 3 at 4:28 PM
$UPB any news out today?
2 · Reply
Xrx12
Xrx12 Sep. 3 at 2:02 PM
$UPB 📉📉📉📉
0 · Reply
Xrx12
Xrx12 Sep. 3 at 1:46 PM
$UPB will probably hit $5.00 here soon
0 · Reply
Gunnar1
Gunnar1 Sep. 2 at 3:17 PM
$UPB Stepping back in here.
1 · Reply
Xrx12
Xrx12 Sep. 2 at 3:10 PM
$UPB here comes the drop
0 · Reply